Post-approval studies (Phase 4)Study completedNCT01660906
What this trial is testing
Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
Who this might be right for
Chronic Phase Chronic Myeloid Leukemia
Bristol-Myers Squibb 39